Objective: Most patients with advanced prostate cancer after prostate-specific antigen (PSA) relapse following maximum androgen blockade rapidly progress to death. The present study was aimed to predict the survival of these serious patients after PSA relapse.
Methods: Sixty-eight patients with M1b and 20 patients with T3b, who relapsed and died of cancer within a short period, were studied. PSA-doubling time (PSA-DT) at PSA relapse influenced the outcome after PSA relapse [hazard ratio (CI): 2.000 (1.283-3.226)]; thus, on the basis of the median values of PSA-DT (>2 months) and additionally nadir PSA in previous treatment (
Results: The patients with PSA-DT of >2 months and nadir PSA of
Conclusion: Both PSA-DT and nadir PSA were predictive factors for subsequent survival at PSA relapse, and the patients with long PSA-DT and low nadir PSA may show long outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jjco/hym153 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SABR tolerance after prostatectomy: pushing the boundaries of ultrahypofractionation.
Clin Transl Oncol
January 2025
Department of Radiation Oncology, HM Hospitales, C/Oña 10, 28050, Madrid, Spain.
Objective: To evaluate the feasibility and tolerance of ultra-hypofractionated SABR (stereotactic ablative radiation therapy) protocol following radical prostatectomy.
Patients And Methods: We included patients undergoing adjuvant or salvage SABR between April 2019 and April 2023 targeting the surgical bed and pelvic lymph nodes up to a total dose of 36.25 Gy (7.
High-Intensity Focused Ultrasound Ablation for Primary or Salvage Prostate Cancer Therapy: Initial Outcomes in the Veteran Healthcare Setting.
Life (Basel)
December 2024
Operative Care Line, Urology Section, Michael E. DeBakey Veteran Affairs Medical Center, Houston, TX 77030, USA.
High-Intensity Focused Ultrasound (HIFU) provides comparable oncologic, erectile, and urinary outcomes to standard-of-care options for localized prostate cancer. This study reports the largest United States series of HIFU in veterans for both primary and salvage therapies. We retrospectively analyzed the outcomes of 43 veterans treated at the Michael E.
View Article and Find Full Text PDFAtypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma.
Biomolecules
December 2024
Department of Translational Medicine, University of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy.
Prostate cancer (PCa) is a high-prevalence disease usually characterized by metastatic spread to the pelvic lymph nodes and bones and the development of visceral metastases only in the late stages of disease. Positron Emission Tomography (PET) plays a key role in the detection of PCa metastases. Several PET radiotracers are used in PCa patients according to the stage and pathological features of the disease, in particular Ga/F-prostate-specific membrane antigen (PSMA) ligands.
View Article and Find Full Text PDFEarly Versus Delayed Androgen Deprivation Therapy for Biochemical Recurrence After Local Curative Treatment in Non-Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of the Literature.
Cancers (Basel)
January 2025
Department of Radiation Oncology, McGill University, Montreal, QC H3A 0G4, Canada.
Background: The ideal timing of androgen deprivation therapy (ADT) for patients with biochemical recurrence (BCR) of prostate cancer (PCa) remains controversial due to its side effects and uncertain impact on survival outcomes.
Methods: We performed a review of the current literature by comprehensively searching the PubMed, Embase, and Cochrane databases to determine the optimal timing of ADT initiation after biochemical recurrence. We selected 26 studies including systematic reviews, randomized controlled trials (RCTs), and retrospective studies, while also reviewing practice guidelines.
Diagnostic Value of Gastrin-Releasing Peptide Receptor-Targeted PET Imaging in Oncology: A Systematic Review.
Semin Nucl Med
January 2025
Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria. Electronic address:
Gastrin-releasing peptide receptor (GRPR), overexpressed in various cancers, is a promising target for positron emission tomography (PET). This systematic review investigated the diagnostic value of GRPR-targeted PET imaging in oncology. A systematic search was conducted on major medical databases until May 23, 2024.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!